Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

Must have received: standard therapy — relapsed/refractory or no standard therapy exists

relapsed from or is refractory to standard therapy or for which no standard therapy exists

Cannot have received: systemic anticancer therapy

Exception: must be >21 days before enrollment

Patient has received any systemic anticancer therapy (including chemotherapy, targeted therapy, biological immunotherapy, any investigational drug, or anti-cancer herbal medicine) within 21 days before enrollment

Cannot have received: blood support therapy (blood transfusion, blood products, hematopoiesis stimulating agents such as granulocyte-colony stimulating factor [G-CSF])

Exception: must be >2 weeks before enrollment

any blood support therapy (including blood transfusion, blood products, or hematopoiesis stimulating agents such as granulocyte-colony stimulating factor [G-CSF]) within 2 weeks before enrollment

Cannot have received: systemic corticosteroids

Exception: dose >10 mg prednisone or equivalent

Patients who are receiving corticosteroids at a dose of > 10 mg prednisone or equivalent of other systemic steroids will be excluded

Cannot have received: Aurora kinase inhibitor

Exception: toxicity leading to discontinuation

Patient has previously experienced toxicity leading to discontinuation of treatment with Aurora kinase inhibitors

Cannot have received: VEGF/VEGFR inhibitor (sorafenib, sunitinib, pazopanib, bevacizumab, regorafenib, axitinib, vandetanib, dasatinib)

Exception: toxicity leading to discontinuation

Patient has previously experienced toxicity leading to discontinuation of treatment with ... VEGF/VEGFR inhibitors, such as sorafenib, sunitinib, pazopanib, bevacizumab, regorafenib, axitinib, vandetanib, or dasatinib